Plecanatide Evidence Guide
Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.
Our Take
Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.
- Evidence context
- IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 3mg oral once daily
Benefits and Evidence
- Chronic Idiopathic Constipation Relief: Level A, includes human evidence - Phase 3 trials demonstrate significant improvement in complete spontaneous bowel movements (CSBMs) compared to placebo. Approximately 21% of patients achieved primary endpoint vs. 10% placebo.
- IBS-C Symptom Improvement: Level A, includes human evidence - Significant improvement in both abdominal pain and bowel movement frequency in IBS-C patients. FDA-approved for this indication based on rigorous Phase 3 data.
- Diarrhea (Adverse): Level A, includes human evidence - Diarrhea is the most common adverse effect, occurring in approximately 2-5% of patients. Usually mild and self-limiting but may lead to discontinuation.
Side Effects and Warnings
- Diarrhea (most common, 2-5%)
- Abdominal distension
- Flatulence
- Abdominal tenderness
- Sinusitis
- Upper respiratory tract infection
- Contraindicated in patients under 6 years of age (risk of serious dehydration)
- Avoid use in patients 6 to less than 18 years of age
Research Dosage References
- <strong>Oral</strong> - 3 mg - Once daily - FDA-approved dose for both CIC and IBS-C. Take with or without food. Tablet should be swallowed whole or crushed and mixed with applesauce or water.
Mechanism of Action
Plecanatide activates intestinal fluid secretion through: 1. GC-C receptor binding: Binds to guanylate cyclase-C receptors on the luminal surface of intestinal epithelial cells in a pH-dependent manner, with optimal activity in the slightly acidic proximal small intestine. 2. Cyclic GMP elevation: Stimulates intracellular and extracellular cGMP production, activating downstream signaling cascades. 3. CFTR activation: cGMP activates protein kinase GII, which phosphorylates the cystic fibrosis transmembrane conductance regulator (CFTR), opening chloride channels. 4. Fluid secretion: Increased chloride and bicarbonate secretion draws water into the intestinal lumen, softening stool and accelerating transit. 5. Visceral pain reduction: Elevated extracellular cGMP may reduce visceral hypersensitivity by modulating pain-sensing afferent neurons.
Legal Status
FDA-approved (Trulance) since January 2017 for CIC, and March 2018 for IBS-C. Prescription required. Available in the United States. Patent-protected.
Primary Sources
- Efficacy and safety of plecanatide in patients with chronic idiopathic constipation. Am J Gastroenterol, 2017.
- Plecanatide for irritable bowel syndrome with constipation: Phase 3 trial results. Am J Gastroenterol, 2018.
- Uroguanylin and guanylin peptide analogs as regulators of intestinal function. World J Gastroenterol, 2015.
Quick Answers
Where is the strongest evidence for Plecanatide?
Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide. Evidence context: IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism research.
What are the main side effects of Plecanatide?
Plecanatide side effects and warning signals include Diarrhea (most common, 2-5%), Abdominal distension, Flatulence, Abdominal tenderness, and Sinusitis.
What evidence level is Plecanatide?
Plecanatide is rated Level A; the listed research status is FDA Approved.